SciSparc announces publication of patent via Clearmind collaboration

SciSparc (SPRC) announced its collaboration with Clearmind Medicine (CMND) has led to the publication of a patent application by the South Korean Intellectual Property Office. The patent application relates to a combination treatment using Clearmind’s 5-methoxy-2-aminoindane and SciSparc’s Palmitoylethanolamide for the treatment of cocaine addiction. The patent is based on preclinical trial results led by Professor Gal Yadid and his team at the Gonda Multidisciplinary Brain Research Center at Bar-Ilan University in Israel. These results followed an earlier experiment in which animals treated with MEAI exhibited a significant reduction in cocaine-induced craving. Building on these findings, further research assessed whether MEAI’s effect on drug-seeking behavior extends to natural rewards, as reward-based reinforcement is a fundamental survival mechanism across species. The study produced positive results, demonstrating that while MEAI reduced cocaine-seeking behavior, it did not impair the rats’ response to natural rewards, such as sucrose. This suggests that MEAI’s effect on drug craving is not linked to the general reward system but rather specifically targets drug-related compulsions. This latest publication adds to multiple patent applications already filed in the U.S. and other global territories as part of the ongoing SciSparc-Clearmind collaboration.